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LETTERS TO THE EDITOR
Coronary Endothelial Dysfunction in the
Early Months After Heart Transplantation
We read with interest the report by Aptecar et al. (1) that early
after heart transplantation, coronary vasodilator effects of bradyki-
nin are preserved despite abnormal response to intracoronary
injection of acetylcholine. This absence of alterations to the
vasodilator action of bradykinin is neither a new nor an
unexpected finding. In cardiac transplant recipients with normal
angiography, this preservation of the coronary response to endoge-
nous vasodilator peptides has already been reported not only for
substance P (2), as mentioned by Aptecar et al. (1), but also for
bradykinin (3). In contrast to acetylcholine and serotonin, bradykinin
and substance P are potent endothelium-dependent vasodilators.
Their endothelial vasodilator effects are not counterbalanced by a
direct constriction mediated by the stimulation of smooth muscle
receptors.
As pointed out in our previous study (3) also performed in the
early months following transplantation, the hypersensitivity to the
vasoconstrictor effect of serotonin is not directly related to a
decrease in endothelium-derived nitric oxide (NO) availability.
Indeed, acute L-arginine supplementation in transplant recipients,
as compared to hyperlipidemic patients, did not modify the
hypersensitivity to serotonin (3).
Immune processes such as cytokines produced by activated
macrophages and T cells play a major role in these abnormal
responses, probably even in the absence of rejection episodes (4).
First, this inflammatory response may promote the release of
endothelin, an endothelium-derived contracting factor (EDCF)
able to potentiate the vasoconstriction to various amines (5) and
seems to play a major role in the development of the graft
vasculopathy (6,7). Second, cytokines may also activate the induc-
ible isoform of nitric oxide synthase (iNOS), promoting the release
of potent oxidants such as superoxide anion and peroxynitrite (8).
In line with this hypothesis, the coronary vasoconstriction to
acetylcholine was enhanced in patients with rejection episodes
cited in Aptecar et al. (1).
Hence, from available data, it is unlikely that the coronary
endothelial NO synthase pathway is impaired early after heart
transplantation. The abnormal responses to serotonin and acetyl-
choline are probably related to the presence of EDCF and/or
changes in smooth muscle receptors. Therefore, a direct action on
the endothelial NO synthase via an enhanced bradykinin availabil-
ity by long-term angiotensin-converting enzyme (ACE) inhibi-
tion, as suggested by Aptecar et al. (1), should not markedly
improve the endothelial function.
Furthermore, according to animal studies (9), NO formation is
already enhanced by activation of iNOS in the early months after
transplantation. This enhanced NO availability may explain the
elevated resting coronary blood flow observed in the transplant
recipients of Aptecar et al. (1), which is congruent with previous
studies (10).
Therefore, therapeutical approaches, aiming at counteracting
these abnormalities, with endothelin antagonists or/and antioxi-
dants, seem more appealing than with ACE inhibitors, which may
worsen cyclosporine-induced nephrotoxicity.
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Diurnal Rhythms and
Hemostatic Factors in Atrial Fibrillation
In a recent publication, Li-Saw-Hee et al. (1) measured plasma
concentrations of soluble p-selectin, von Willebrand factor, soluble
thrombomodulin and fibrinogen at 6-h intervals in patients with
atrial fibrillation and detected no variation in levels of these
hemostatic factors over a 24-h period. On the basis of these results,
it was concluded that atrial fibrillation was associated with a loss of
diurnal variation in these hemostatic factors, and that this could
contribute to the high risk of stroke and thromboembolic compli-
cations in this condition. However, we believe that there are a
number of issues related to the experimental design and data
interpretation of this study that cast doubt on the validity of these
conclusions.
First, measurement of hemostatic factors was performed at 6-h
intervals: 12 midnight, 6 AM, 12 noon, and 6 PM. While this may
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